PortfoliosLab logoPortfoliosLab logo
PLX vs. SCHD
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

PLX vs. SCHD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protalix BioTherapeutics, Inc. (PLX) and Schwab U.S. Dividend Equity ETF (SCHD). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PLX achieves a 32.78% return, which is significantly higher than SCHD's 20.66% return. Over the past 10 years, PLX has underperformed SCHD with an annualized return of -9.52%, while SCHD has yielded a comparatively higher 12.34% annualized return.


PLX

1D
-2.05%
1M
14.35%
6M
13.81%
YTD
32.78%
1Y
69.50%
3Y*
10.12%
5Y*
8.09%
10Y*
-9.52%

SCHD

1D
0.49%
1M
-0.00%
6M
16.13%
YTD
20.66%
1Y
23.51%
3Y*
14.13%
5Y*
9.00%
10Y*
12.34%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PLX vs. SCHD - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PLX
Protalix BioTherapeutics, Inc.
32.78%-4.26%5.62%29.93%64.72%-77.09%10.67%5.47%-52.96%48.58%
SCHD
Schwab U.S. Dividend Equity ETF
20.66%4.34%11.66%4.54%-3.26%29.87%15.03%27.29%-5.56%20.85%

Correlation

The correlation between PLX and SCHD is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2011

0.17

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PLX vs. SCHD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PLX
PLX Risk / Return Rank: 7575
Overall Rank
PLX Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
PLX Sortino Ratio Rank: 7373
Sortino Ratio Rank
PLX Omega Ratio Rank: 7676
Omega Ratio Rank
PLX Calmar Ratio Rank: 7777
Calmar Ratio Rank
PLX Martin Ratio Rank: 7171
Martin Ratio Rank

SCHD
SCHD Risk / Return Rank: 8686
Overall Rank
SCHD Sharpe Ratio Rank: 8585
Sharpe Ratio Rank
SCHD Sortino Ratio Rank: 9090
Sortino Ratio Rank
SCHD Omega Ratio Rank: 8282
Omega Ratio Rank
SCHD Calmar Ratio Rank: 9393
Calmar Ratio Rank
SCHD Martin Ratio Rank: 8181
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PLX vs. SCHD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Schwab U.S. Dividend Equity ETF (SCHD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PLXSCHDDifference
Sharpe ratioReturn per unit of total volatility

-1.08

Sortino ratioReturn per unit of downside risk

-1.65

Omega ratioGain probability vs. loss probability

1.23

1.38

-0.15

Calmar ratioReturn relative to maximum drawdown

1.76

5.12

-3.36

Martin ratioReturn relative to average drawdown

3.03

12.47

-9.44

PLX vs. SCHD - Sharpe Ratio Comparison

The current PLX Sharpe Ratio is 1.09, which is lower than the SCHD Sharpe Ratio of 2.17. The chart below compares the historical Sharpe Ratios of PLX and SCHD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PLX vs. SCHD - Drawdown Comparison

The maximum PLX drawdown since its inception was -99.91%, which is greater than SCHD's maximum drawdown of -33.37%. Use the drawdown chart below to compare losses from any high point for PLX and SCHD.


Loading charts...

Drawdown Indicators


PLXSCHDDifference

Max Drawdown

Largest peak-to-trough decline

-99.91%

-33.37%

-66.54%

Max Drawdown (1Y)

Largest decline over 1 year

-39.68%

-4.61%

-35.07%

Max Drawdown (3Y)

Largest decline over 3 years

-56.03%

-16.13%

-39.90%

Max Drawdown (5Y)

Largest decline over 5 years

-73.21%

-16.85%

-56.36%

Max Drawdown (10Y)

Largest decline over 10 years

-94.38%

-33.37%

-61.01%

Current Drawdown

Current decline from peak

-99.73%

-0.03%

-99.70%

Average Drawdown

Average peak-to-trough decline

-93.67%

-3.31%

-90.36%

Ulcer Index

Depth and duration of drawdowns from previous peaks

23.02%

1.89%

+21.13%

Volatility

PLX vs. SCHD - Volatility Comparison

Protalix BioTherapeutics, Inc. (PLX) has a higher volatility of 12.83% compared to Schwab U.S. Dividend Equity ETF (SCHD) at 3.54%. This indicates that PLX's price experiences larger fluctuations and is considered to be riskier than SCHD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PLXSCHDDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.83%

3.54%

+9.29%

Volatility (6M)

Calculated over the trailing 6-month period

43.20%

7.70%

+35.50%

Volatility (1Y)

Calculated over the trailing 1-year period

64.40%

10.93%

+53.47%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

67.68%

14.36%

+53.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.20%

16.70%

+62.50%

Dividends

PLX vs. SCHD - Dividend Comparison

PLX has not paid dividends to shareholders, while SCHD's dividend yield for the trailing twelve months is around 3.22%.


PositionTTM20252024202320222021202020192018201720162015
PLX
Protalix BioTherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SCHD
Schwab U.S. Dividend Equity ETF
3.22%3.82%3.64%3.49%3.39%2.78%3.16%2.98%3.06%2.63%2.89%2.97%

Frequently Asked Questions


PLX and SCHD have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PLX has higher volatility (12.83%) compared to SCHD (3.54%). In terms of maximum drawdown, PLX dropped -99.91% vs SCHD's -33.37%.

SCHD currently has the higher Sharpe Ratio (2.17 vs 1.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PLX and SCHD

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer